View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, Feb. 4 (HealthDay News) -- Makena (hydroxyprogesterone caproate) has been approved by the U.S. Food and Drug Administration to help prevent birth before 37 weeks of pregnancy in women who have had at least one prior early delivery.
Makena, however, is not intended for women who are at greater-than-average risk for preterm birth because they are pregnant with multiple fetuses, the agency said Friday in a news release.
The drug was sanctioned under an accelerated-approval program that requires post-marketing studies that provide additional proof of the medication's benefit, the FDA said.
Makena is designed to be injected into the hip once weekly by a health-care provider, beginning at 16 weeks and no later than 21 weeks of pregnancy.
In clinical testing involving 463 women aged 16 to 43, 37 percent of those who took Makena delivered early, compared with 55 percent among those who didn't take the drug, the FDA said.
The most common side effects were injection site reactions, hives, nausea and diarrhea, the FDA said.
Makena is manufactured by Hologic Inc., of Bedford, Mass.
The U.S. Centers for Disease Control and Prevention has more about preterm birth.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top